Lunai Bioworks Files 8-K on Impairments
Ticker: LNAI · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Lunai Bioworks Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: impairment, 8-K, corporate-actions
TL;DR
Lunai Bioworks (formerly RenovaRx) filed an 8-K on Sept 2, 2025, reporting material impairments.
AI Summary
On September 2, 2025, Lunai Bioworks Inc. filed an 8-K report disclosing material impairments and other events. The company, formerly known as RenovaRx Inc. and Enochian Biosciences Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates potential financial distress or significant changes in the value of company assets, which could impact investor confidence and future operations.
Risk Assessment
Risk Level: medium — Material impairments suggest potential financial instability or significant write-downs of assets, warranting closer investor scrutiny.
Key Players & Entities
- Lunai Bioworks Inc. (company) — Registrant
- RenovaRx Inc. (company) — Former company name
- Enochian Biosciences Inc. (company) — Former company name
- September 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific assets are subject to material impairment?
The filing does not specify the exact assets that are subject to material impairment, only that such impairments are being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on September 2, 2025.
What were Lunai Bioworks Inc.'s previous names?
Lunai Bioworks Inc. was formerly known as RenovaRx Inc. and Enochian Biosciences Inc.
In which state is Lunai Bioworks Inc. incorporated?
Lunai Bioworks Inc. is incorporated in Delaware.
What is the Standard Industrial Classification (SIC) code for Lunai Bioworks Inc.?
The SIC code for Lunai Bioworks Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2025-09-05 17:12:33
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Marke
Filing Documents
- e6829_8-k.htm (8-K) — 27KB
- 0001731122-25-001204.txt ( ) — 187KB
- renb-20250902.xsd (EX-101.SCH) — 3KB
- renb-20250902_lab.xml (EX-101.LAB) — 33KB
- renb-20250902_pre.xml (EX-101.PRE) — 22KB
- e6829_8-k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 2, 2025, the Court of Amsterdam (the "Court") declared bankrupt Gedi Cube B.V. ("Gedi"), an indirect subsidiary of Lunai Bioworks, Inc. ("Lunai"), and appointed Mr. M.M. Dellebeke as the receiver in the bankruptcy. Gedi filed a voluntary petition seeking a declaration of bankruptcy due to its inability to make payments as they became due. The Company is monitoring potential impacts on its supply chain, customer relationships, and ongoing projects that were previously supported by Gedi. Management is implementing contingency plans to mitigate any business disruption. Neither Lunai nor any of its other subsidiaries are filing for bankruptcy protection, and Lunai and its other subsidiaries will continue to operate their businesses as usual.
06 – Material Impairments
Item 2.06 – Material Impairments In connection with the bankruptcy described in Item 8.01, management determined on September 2, 2025 that a material impairment of assets has occurred. The Company expects to record an impairment charge for the quarter ending September 30, 2025, however, is unable to make a good faith estimate of the same or the cash expenditures resulting from the impairment charge, if any, at the time of this filing. The Company expects to report the impairment charge in its quarterly report on Form 10-Q for the quarter ended September 30, 2025 or sooner if available. SIGN A TURES Pursuant to the requ i rements of the S ecurities E xchange Act of 1934, the registrant h a s duly caused this report to be signed on its behalf by t he undersigned hereunto duly authori z ed. LUNAI BIOWORKS, INC. By: /s/ David Weinstein Name: David Weinstein Title: Chief Executive Officer Date : September 5, 2025